Takeda To Start New Alogliptin Trial In U.S. To Meet FDA Requirement
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical says it has decided to conduct another clinical trial in the United States for its SYR-322 (alogliptin) diabetes drug. U.S. FDA told Takeda in June it would need additional trials before it could approve the drug for treating Type 2 diabetes. FDA said it was not satisfied with the data provided by Takeda to show the drug met cardiovascular safety requirements. Takeda plans to begin the new trial in September with expectations the drug could reach the U.S. market early in 2012. (Click here for more - a subscription may be required
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.